ProShares Ultra NASDAQ Biotechnology
BIB
30 hedge funds and large institutions have $19M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
15% more call options, than puts
Call options by funds: $7.58M | Put options by funds: $6.62M
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
11% more funds holding
Funds holding: 27 → 30 (+3)
0.28% less ownership
Funds ownership: 9.29% → 9.01% (-0.28%)
4% less capital invested
Capital invested by funds: $19.7M → $19M (-$697K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.5M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.09M |
| 3 |
HF
HRT Financial
New York
|
+$1.78M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$809K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$8.54M |
| 2 |
SW
SkyOak Wealth
Southfield,
Michigan
|
-$690K |
| 3 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$355K |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$231K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$43.3K |
BIB Hedge Fund Activity: Q3 2020 in Review
30 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2020, worth a combined $19M — down 3.5% from $19.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BIB positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $3.5M. The largest seller was Geneos Wealth Management, cutting an estimated $8.54M.
- 30 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2020, up from 27 in Q2 2020.
- Funds reported $19M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2020, down 3.5% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2020 and 2 closed out, a net change of +3 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2020 was Tower Research Capital (TRC), an estimated $3.5M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2020 was Geneos Wealth Management, an estimated $8.54M sold.
Based on aggregated 13F filings for Q3 2020.